MedPath

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Phase 3
Completed
Conditions
Euvolemic Hyponatremia
Interventions
Drug: Placebo
Registration Number
NCT00876798
Lead Sponsor
CardioKine Inc.
Brief Summary

The purpose of this study is to evaluate the safety and tolerability of oral lixivaptan capsules in subjects with Euvolemic Hyponatremia.

Detailed Description

Phase I and Phase II clinical trials have demonstrated that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with HF, LCWA, and SIADH. Lixivaptan was previously evaluated in disease states characterized by hyponatremia with euvolemia (SIADH) and hyponatremia combined with fluid overload (HF, LCWA). Lixivaptan demonstrated correction in serum sodium concentration together with marked aquaresis in subjects with hyponatremia.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
206
Inclusion Criteria
  1. Written informed consent.
  2. Men or women aged 18 or older.
  3. Diagnosis of euvolemic hyponatremia (Na+ < 135 mEq/L).
  4. Willing to be observed in a monitored setting for approximately the first 8 hours following treatment initiation (first dose).
  5. In the Investigator's judgement the patient has adequate visual and auditory acuity to allow participation in the trial.
Exclusion Criteria
  1. Pregnant or breast-feeding women, or women planning to become pregnant or to breastfeed.
  2. Overt symptoms of hyponatremia requiring immediate medical intervention (e.g., coma, seizures).
  3. Acute or transient hyponatremia (e.g., associated with head trauma, postoperative state, or use of radiotherapy and/or chemotherapy).
  4. Hyponatremia in hypovolemic states (e.g., due to fluid loss through vomiting, diarrhea, burns, etc.). Hypovolemic hyponatremia is defined as the presence of clinical evidence of extracellular fluid volume depletion.
  5. Hyponatremia in hypervolemic states (e.g., congestive heart failure). Hypervolemia is defined as a presence of increased total body water with signs of edema.
  6. Pseudohyponatremia (i.e., hyponatremia resulting from a laboratory artifact).
  7. Hypertonic hyponatremia (e.g., hyponatremia in the setting of hyperglycemia).
  8. Hyponatremia as a result of any medication that can safely be withdrawn.
  9. Hyponatremia due to hypothyroidism or adrenal insufficiency.
  10. Current diagnosis of psychogenic polydipsia.
  11. Receiving within 7 days of enrollment other medication for treatment of hyponatremia, specifically: demeclocycline, lithium carbonate, urea, or any vasopressin antagonist.
  12. Supine systolic arterial blood pressure of ≤ 90 millimeters of mercury (mmHg).
  13. Serum creatinine > 3.0 mg/dL (> 265.2 mol/L).
  14. Hypokalemia based on clinical sign/symptoms or lab findings (e.g., serum potassium < 3.5 mEq/L).
  15. Uncontrolled diabetes mellitus as defined by the Investigators (e.g., hemoglobin - glycosylated [HbA1c] > 9%).
  16. ST-segment elevation myocardial infarction (STEMI) within 30 days or active myocardial ischemia at the time of enrollment.
  17. History of cerebral vascular accident (CVA) within 30 days prior to screening.
  18. Severe malnutrition in the Investigator's judgment (e.g., body mass index [BMI] < 17).
  19. Advanced liver disease or documented diagnosis of cirrhosis or alcoholic hepatitis.
  20. Urinary tract obstruction (benign prostatic hypertrophy [BPH] allowed if non-obstructive).
  21. History of chronic drug/medication abuse within the past 6 months or current alcohol abuse.
  22. Terminally ill or moribund condition with little chance of short-term survival.
  23. Receiving vasopressin or its analogs for treatment of any condition.
  24. Known allergy to any vasopressin antagonist.
  25. Previous participation in a lixivaptan study.
  26. Recipient of any investigational treatment within 30 days prior to baseline visit.
  27. Unable to take oral medications.
  28. Significant neurological disorders (e.g., permanent neurological deficits, probable Alzheimer's disease, normal pressure hydrocephalus, Parkinsonian dementia complex, multi-infarct dementia, mixed dementia, or Huntington's disease).
  29. Conditions limiting access to water or an inability to respond to thirst (e.g., hydrophobia, or non-communicative).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2PlaceboPlacebo
1LixivaptanLixivaptan
Primary Outcome Measures
NameTimeMethod
To demonstrate that lixivaptan is safe and effective in achieving and maintaining increased serum sodium concentration in subjects with SIADH and other conditions of euvolemic hyponatremia.6 months
Secondary Outcome Measures
NameTimeMethod
If lixivaptan demonstrates improvement in serum sodium, % of subjects achieving normalized serum sodium, % of subjects requiring fluid restriction, prevention of worsening hyponatremia, and the change from baseline to complete TMT-B.6 months

Trial Locations

Locations (89)

Innovative Research of West Florida, Inc.

🇺🇸

Clearwater, Florida, United States

Galiz Research

🇺🇸

Miami, Florida, United States

Miami Jewish Home and Hospital for the Aged

🇺🇸

Miami, Florida, United States

Nephrology Associates of South Miami

🇺🇸

Miami, Florida, United States

Royal Care Nursing Home

🇺🇸

Fountain Valley, California, United States

Executive Health and Research Associates

🇺🇸

Atlanta, Georgia, United States

RTR Medical Group

🇺🇸

Savannah, Georgia, United States

Four Rivers Clinical Research

🇺🇸

Paducah, Kentucky, United States

Levindale Hebrew Geriatric Center and Hospital

🇺🇸

Baltimore, Maryland, United States

LifeBridge Health, Inc./ Courtland Gardens Nursing & Rehabilitation Center

🇺🇸

Baltimore, Maryland, United States

Stephen R. Smith

🇺🇸

Baltimore, Maryland, United States

Genesis Clinical Research & Consulting, LLC

🇺🇸

Fall River, Massachusetts, United States

Mercury Street Medical Group

🇺🇸

Butte, Montana, United States

Memorial Hermann - Memorial City Research Center

🇺🇸

Houston, Texas, United States

Clinical Research and Consulting Center

🇺🇸

Fairfax, Virginia, United States

Presidio ospedaliero zona aretina, Ospedale San Donato di Arezzo

🇮🇹

Pietro Nenni, Arezzo, Italy

Medicina II, Arcispedale Santa Maria Nuova

🇮🇹

Reggio Emilia, Italy

SOD Clinica di Endocrinologia a Malatte del Metabolismo

🇮🇹

Torette di Ancona, Italy

Birmingham Nursing and Rehabilitation East

🇺🇸

Birmingham, Alabama, United States

PsyPharma Clinical Research, Inc.

🇺🇸

Phoenix, Arizona, United States

COR Clinical Research LLC

🇺🇸

Oklahoma City, Oklahoma, United States

Hilltop Physicians Inc

🇺🇸

Cincinnati, Ohio, United States

InVisions Consultants, LLC

🇺🇸

San Antonio, Texas, United States

Rochester General Hospital

🇺🇸

Rochester, New York, United States

Coastal Nephrology Associates Reserach Center

🇺🇸

Port Charlotte, Florida, United States

Toulon Health Care Center

🇺🇸

Toulon, Illinois, United States

Southern Arizona VA Health Care System (SAVAHCS)

🇺🇸

Tucson, Arizona, United States

Parkview Rehabilitation and Nursing

🇺🇸

Little Rock, Arkansas, United States

Healthscan Research, LLC

🇺🇸

Montgomery, Alabama, United States

Searcy Medical Center

🇺🇸

Searcy, Arkansas, United States

AV Institute, Inc.

🇺🇸

Carson, California, United States

Sarah S. Olelewe, MD, Inc.

🇺🇸

Hawthorne, California, United States

Olive View - UCLA Medical Center

🇺🇸

Sylmar, California, United States

Torrance Clinical Research

🇺🇸

Lomita, California, United States

Naples Institute for Clinical Research

🇺🇸

Bonita Springs, Florida, United States

Jacksonville Center for CLinical Research

🇺🇸

Jacksonville, Florida, United States

Scientific Clinical Research, Inc.

🇺🇸

North Miami, Florida, United States

Piedmont Clinical Trials

🇺🇸

North Miami, Florida, United States

Rockdale Medicall Research Associates

🇺🇸

Conyers, Georgia, United States

Natchitoches Internal Medicine

🇺🇸

Natchitoches, Louisiana, United States

Research Integrity, LLC

🇺🇸

Owensboro, Kentucky, United States

Western New England Renal & Transplant Assciates, PC

🇺🇸

Springfield, Massachusetts, United States

SLU Care Doctors Office Building

🇺🇸

Saint Louis, Missouri, United States

Millenium Psychiatric Associates

🇺🇸

St Louis, Missouri, United States

Buffalo VA Medical Center

🇺🇸

Buffalo, New York, United States

Erie County Medical Center/SUNY at Buffalo affiliate

🇺🇸

Buffalo, New York, United States

Internal Medical Associates of Grand Island, PC

🇺🇸

Grand Island, Nebraska, United States

Parker Jewish Institute for Health Care and Rehabilitation

🇺🇸

New Hyde PArk, New York, United States

Medical Research Development Associates, LLC

🇺🇸

Springfield Gardens, New York, United States

Three Rivers Health and Rehabilitation

🇺🇸

Windsor, North Carolina, United States

Lillestol Research LLC

🇺🇸

Fargo, North Dakota, United States

Valley Medical Research

🇺🇸

Centerville, Ohio, United States

Providence Health Partners - Center for Clinical Research

🇺🇸

Dayton, Ohio, United States

Your Diabetes Endocrine Nutrition Group, Inc.

🇺🇸

Mentor, Ohio, United States

Carolina Diabetes and Kidney Center

🇺🇸

Sumter, South Carolina, United States

Northeast Clinical Research Center

🇺🇸

Bethlehem, Pennsylvania, United States

Translational Neuroscience, LLC/Drexel University College of Medicine

🇺🇸

Conshohocken, Pennsylvania, United States

Ilumina CLinical Associates

🇺🇸

Indiana, Pennsylvania, United States

Senior Adults Specialty Research

🇺🇸

Austin, Texas, United States

South Texas Institutes of Health

🇺🇸

McAllen, Texas, United States

ASpen CLinical Research

🇺🇸

Orem, Utah, United States

McGuire VA Medical Center

🇺🇸

Richmond, Virginia, United States

Universal Research Group

🇺🇸

Tacoma, Washington, United States

Universal Clinical Research & Technology, Inc.

🇺🇸

Orlando, Florida, United States

University Clinical Research & Technology, Inc.

🇺🇸

Orlando, Florida, United States

Senior Care of Colorado, PC

🇺🇸

Aurora, Colorado, United States

Apollo Hospitals

🇮🇳

Tanil Nadu, Chennai, India

Hadassah Medical Organization, Hadassah University Hospital, Ein Karem

🇮🇱

Kiryat Hadassah, Jerusalem, Israel

The Endocrine Institute, Rabin Medical Center, Beilinson Hospital

🇮🇱

Petah Tikvah, Israel

Hospital Nacional Guillermo Almenara Irigoyen-EsSalud.

🇵🇪

Lima, Peru

Bhatia Hospital, G-1 Ward

🇮🇳

Mumbia, Maharashtra, India

Jehangir Clinical Development Centre Pvt. Ltd.

🇮🇳

Pune, Maharashtra, India

Kovai Medical Centre & Hospital

🇮🇳

Tamil Nadu, Coimbatore, India

Hospital Nacional Arzobispo Loayza

🇵🇪

Lima, Peru

Dayanand Medical College and Hospital

🇮🇳

Tagore Nagar, Ludhiana, India

Instituto Biomedico de Investigacion A.C.

🇲🇽

Aguascalientes, Mexico

PsyPharma Clinical Research

🇺🇸

Phoenix, Arizona, United States

Hospital Erasme

🇧🇪

Bruzelles, Belgium

Smt G.R. Doshi & Smt K.M. Mehta Institute of Kidney Diseases & Reseacrh Cnetre (IKDRC) & Dr. H.L. Trivedi Institute of Transplantation Services (ITS)

🇮🇳

Asarwa, Ahmedabad, India

Kamineni Hospitals

🇮🇳

Hyderabad, Andhra Pradesh, India

M. S. Ramaiah Memorial Hospital

🇮🇳

Bangalore, Karnataka, India

Justice K. S. Hedge Charitable Hospital

🇮🇳

Karnataka, Mangalore, India

Department of Neurology St. John's Medical College & Hospital

🇮🇳

Bangalore, India

Tel Aviv Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

John J. Hainkel Jr Home and Rehabilitation Center

🇺🇸

New Orleans, Louisiana, United States

Fakultni nemocnice Ostrava Neurologicke oddeleni

🇨🇿

Ostrava, Poruba, Czech Republic

Klinika nefrologie VFN a 1.LF UK

🇨🇿

Nemocnice 2, Praha, Czech Republic

Diabetic and Endocrine Unit, Hillel Yaffe Medical Center

🇮🇱

Hadera, Israel

Hospital General "Dr. Santiago Ramon Y Cajal" I.S.S.S.T.E.

🇲🇽

Durango, Mexico

© Copyright 2025. All Rights Reserved by MedPath